Latest News - Promius

Tuesday, November 14, 2017

Promius Pharma Employees Fundraise for Hurricane Victims

Promius Pharma LLC's employees raised $12,715 to support American Red Cross relief efforts to assist those affected by the recent hurricanes. Additionally, Promius' parent company Dr. Reddy…

Read the full story

Wednesday, August 03, 2016

Dr. Reddy’s Sernivo Officially Debuts at NYC Media Event

Calling Sernivo (betamethasone dipropionate) Spray 0.05% a ‘trifecta’ for dermatologists who treat mild-to-moderate psoriasis, Josh Zeichner, MD, introduced members of the New York City me…

Read the full story

Wednesday, June 01, 2016

Sernivo Spray Hits Pharmacy Shelves

Sernivo™ Spray for psoriasis is officially available. Dr. Reddy’s Laboratories’ US subsidiary, Promius Pharma, LLC, U.S. Sernivo™ Spray (betamethasone dipropionate) 0.05% wa…

Read the full story

Tuesday, March 01, 2016

Dermwire’s Inside Scoop on Hottest Expected AAD2016 Launches

The American Academy of Dermatology (AAD)’s annual meeting is the place for skin care companies looking to launch the latest -- and hopefully greatest  --- innovations or iterations in sk…

Read the full story

Tuesday, February 09, 2016

FDA Awards Tentative Approval for Zenavod to Treat Rosacea

The FDA awarded Dr. Reddy's Laboratories tentative approval for Zenavod™ (doxycycline) Capsules, 40mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory l…

Read the full story

Monday, February 08, 2016

Promius Receives FDA Approval for Sernivo Spray for Psoriasis

Dr. Reddy’s US subsidiary Promius Pharma received FDA approval for Sernivo (betamethasone dipropionate) Spray 0.05%. Sernivo Spray, a prescription topical steroid, is indicated for the treatment…

Read the full story

Wednesday, October 28, 2015

Phase 3 Data Show Promius Pharma’s DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasis

Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the prop…

Read the full story

Friday, April 10, 2015

Dr. Reddy’s and its Subsidiary Promius Pharma File Three NDAs

Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr.…

Read the full story

Wednesday, March 25, 2015

Promius Pharma Launches Zenatane 30mg Dose

Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to d…

Read the full story

Friday, March 06, 2015

Promius Pharma, LLC to Market, Distribute Trianex 0.05%

Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-pote…

Read the full story